MX2008009886A - Anticuerpos que enlazan par-2. - Google Patents
Anticuerpos que enlazan par-2.Info
- Publication number
- MX2008009886A MX2008009886A MX2008009886A MX2008009886A MX2008009886A MX 2008009886 A MX2008009886 A MX 2008009886A MX 2008009886 A MX2008009886 A MX 2008009886A MX 2008009886 A MX2008009886 A MX 2008009886A MX 2008009886 A MX2008009886 A MX 2008009886A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- par
- derivatives
- polypeptides
- methods
- Prior art date
Links
- 101100406879 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) par-2 gene Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 abstract 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 3
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 abstract 3
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona composiciones y métodos con relación a o derivado de los anticuerpos anti-PAR-2. En modalidades particulares, la invención proporciona anticuerpos que unen PAR-2 humano, fragmentos y derivados que enlazan a PAR-2 de tales anticuerpos, y polipéptidos que enlazan a PAR-2 comprenden tales fragmentos. Otras modalidades proporcionan ácidos nucleicos que codifican tales anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, las células comprenden tales polinucleótidos, métodos de hacer tales anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, y métodos para usar tales anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, que incluyen métodos de tratar o diagnosticar, a sujetos que tienen trastornos o condiciones relacionados con PAR-2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77245606P | 2006-02-10 | 2006-02-10 | |
| PCT/US2007/003796 WO2007092640A2 (en) | 2006-02-10 | 2007-02-09 | Antibodies that bind par-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008009886A true MX2008009886A (es) | 2008-10-23 |
Family
ID=38345850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008009886A MX2008009886A (es) | 2006-02-10 | 2007-02-09 | Anticuerpos que enlazan par-2. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7888482B2 (es) |
| EP (1) | EP1981913B1 (es) |
| JP (1) | JP5255453B2 (es) |
| AU (1) | AU2007212195B2 (es) |
| CA (1) | CA2638849C (es) |
| ES (1) | ES2476892T3 (es) |
| MX (1) | MX2008009886A (es) |
| WO (1) | WO2007092640A2 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008001887A1 (es) * | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| WO2009020748A2 (en) * | 2007-07-16 | 2009-02-12 | Avaxia Biologics, Inc. | Antibody therapy for modulating function of intestinal receptors |
| EP2244735A4 (en) | 2007-10-02 | 2011-02-23 | Avaxia Biologics Inc | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE |
| EP2313110A1 (en) * | 2008-08-05 | 2011-04-27 | Boehringer Ingelheim International GmbH | Effectors of par-2 activation and their use in the modulation of inflammation |
| WO2010132954A1 (en) * | 2009-05-21 | 2010-11-25 | Oral Health Australia Pty Ltd | Method of treating periodontal disease by administering antagonists of par-2 |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| MY162557A (en) | 2010-02-26 | 2017-06-15 | Oral Health Australia Pty Ltd | Treatment or prevention of infection |
| WO2012077105A2 (en) * | 2010-12-07 | 2012-06-14 | Bio-Marcare Technologies Ltd. | Biomarkers for detecting a cancerous state in a subject |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| WO2015035215A1 (en) | 2013-09-05 | 2015-03-12 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| WO2015048245A1 (en) | 2013-09-25 | 2015-04-02 | Vertex Pharmaceuticals Incorporated | Imidazopyridazines useful as inhibitors of the par-2 signaling pathway |
| AU2015259053B2 (en) | 2014-05-16 | 2020-12-24 | Amgen Inc. | Assay for detecting Th1 and Th2 cell populations |
| JP7672196B2 (ja) | 2017-03-14 | 2025-05-07 | アムジエン・インコーポレーテツド | 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節 |
| JP7418337B2 (ja) * | 2018-02-09 | 2024-01-19 | ジェネンテック， インコーポレイテッド | マスト細胞媒介性炎症性疾患の治療法及び診断法 |
| EP3775251A1 (en) | 2018-03-26 | 2021-02-17 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| WO2020201572A1 (en) | 2019-04-05 | 2020-10-08 | Université De Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| CA3152547A1 (en) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Methods of producing antibody compositions |
| US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| EP4454659A3 (en) | 2020-08-18 | 2025-01-22 | Cephalon LLC | Anti-par-2 antibodies and methods of use thereof |
| CN112229996A (zh) * | 2020-08-25 | 2021-01-15 | 深圳市第二人民医院(深圳市转化医学研究院) | 蛋白酶激活受体2作为宫颈癌转移检测标志物的应用 |
| JP2023548767A (ja) | 2020-10-15 | 2023-11-21 | アムジエン・インコーポレーテツド | 抗体製造方法における相対不対グリカン |
| WO2022261021A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| EP4413377A1 (en) | 2021-10-05 | 2024-08-14 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| GB202204159D0 (en) * | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| AU2024256160A1 (en) | 2023-04-20 | 2025-10-02 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025038600A1 (en) | 2023-08-14 | 2025-02-20 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874400A (en) | 1993-07-26 | 1999-02-23 | Cor Therapeutics | Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
| US5629174A (en) | 1993-07-26 | 1997-05-13 | Cor Therapeutics, Inc. | Recombinant C140 receptor |
| AU5895500A (en) * | 1999-06-29 | 2001-01-31 | Cor Therapeutics, Inc. | Novel indazole peptidomimetics as thrombin receptor antagonists |
| WO2001052883A1 (en) | 2000-01-20 | 2001-07-26 | Amgen Inc. | Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics |
| WO2004080373A2 (en) | 2003-03-11 | 2004-09-23 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) |
| AR070911A1 (es) | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| EP2313110A1 (en) | 2008-08-05 | 2011-04-27 | Boehringer Ingelheim International GmbH | Effectors of par-2 activation and their use in the modulation of inflammation |
-
2007
- 2007-02-08 US US11/704,529 patent/US7888482B2/en active Active
- 2007-02-09 WO PCT/US2007/003796 patent/WO2007092640A2/en not_active Ceased
- 2007-02-09 EP EP07763386.5A patent/EP1981913B1/en active Active
- 2007-02-09 MX MX2008009886A patent/MX2008009886A/es active IP Right Grant
- 2007-02-09 AU AU2007212195A patent/AU2007212195B2/en active Active
- 2007-02-09 JP JP2008554427A patent/JP5255453B2/ja active Active
- 2007-02-09 CA CA2638849A patent/CA2638849C/en active Active
- 2007-02-09 ES ES07763386.5T patent/ES2476892T3/es active Active
-
2011
- 2011-01-18 US US13/008,736 patent/US8287872B2/en active Active
-
2012
- 2012-09-27 US US13/629,373 patent/US20130189281A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2476892T3 (es) | 2014-07-15 |
| AU2007212195A1 (en) | 2007-08-16 |
| CA2638849A1 (en) | 2007-08-16 |
| US20070237759A1 (en) | 2007-10-11 |
| EP1981913B1 (en) | 2014-06-25 |
| CA2638849C (en) | 2014-07-08 |
| WO2007092640A3 (en) | 2008-01-10 |
| EP1981913A2 (en) | 2008-10-22 |
| US7888482B2 (en) | 2011-02-15 |
| US8287872B2 (en) | 2012-10-16 |
| AU2007212195B2 (en) | 2012-02-02 |
| US20110165171A1 (en) | 2011-07-07 |
| JP5255453B2 (ja) | 2013-08-07 |
| US20130189281A1 (en) | 2013-07-25 |
| WO2007092640A2 (en) | 2007-08-16 |
| JP2009525758A (ja) | 2009-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008009886A (es) | Anticuerpos que enlazan par-2. | |
| MX2009013824A (es) | Proteinas de enlace de antigeno que enlazan par-2. | |
| PH12012501006A1 (en) | Compositions and methods relating to anti-igf-1 receptor antibodies | |
| MX2009002571A (es) | Anticuerpos anti-activina a y usos de los mismos. | |
| WO2008136848A3 (en) | Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease | |
| UA96139C2 (uk) | Антитіло до нейропіліну-1 (nrp1) | |
| HK1208236A1 (en) | Antigen binding proteins that bind ccr2 | |
| MX2009009379A (es) | Metodos y composiciones para tratar enfermedades tumorales. | |
| MY162624A (en) | Antibodies directed to her-3 and uses thereof | |
| TW200745163A (en) | Peptides that block the binding of IgG to FcRn | |
| WO2008077945A3 (en) | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies | |
| EP3447074A3 (en) | Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor | |
| WO2009139853A3 (en) | Human monoclonal antibodies against human chemokine receptor ccr7 | |
| WO2010031749A9 (en) | Compositions and methods for detecting tlr3 | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| WO2007131133A8 (en) | Methods and compositions relating to zpa polypeptides | |
| WO2007111661A3 (en) | Human antibodies specific for gastrin materials and methods | |
| WO2006029176A3 (en) | Cancer-testis antigens | |
| WO2004066933A3 (en) | Compositions and methods for treating cancer using igsf9 and liv-1 | |
| WO2007075915A3 (en) | Monoclonal antibodies against orthopoxviruses | |
| WO2007011765A3 (en) | Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides | |
| UA98632C2 (ru) | Антагонистические антитела к notch3 и их применение для профилактики и лечения связанных с notch3 заболеваний | |
| WO2007065124A3 (en) | Methods of identifying and treating individuals exhibiting complex karyotypes | |
| WO2006091326A8 (en) | Anti-prl-3 antibodies and methods of use thereof | |
| AU2016219676A1 (en) | Anti-activin A antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |